Stroke prevention in the elderly atrial fibrillation patient with comorbid conditions: focus on non-vitamin K antagonist oral anticoagulants

References

• GoASHylekEMPhillipsKAPrevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) StudyJAMA2001285182370237511343485
   PubMed Web of Science ®Google Scholar
• JanuaryCTWannLSAlpertJS2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm SocietyJ Am Coll Cardiol20146421e1e7624685669
   PubMed Web of Science ®Google Scholar
• HylekEMD’AntonioJEvans-MolinaCSheaCHenaultLEReganSTranslating the results of randomized trials into clinical practice: the challenge of warfarin candidacy among hospitalized elderly patients with atrial fibrillationStroke20063741075108016527999
   PubMed Web of Science ®Google Scholar
• Lloyd-JonesDMWangTJLeipEPLifetime risk for development of atrial fibrillation: the Framingham Heart StudyCirculation200411091042104615313941
   PubMed Web of Science ®Google Scholar
• MiyasakaYBarnesMEGershBJSecular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalenceCirculation2006114211912516818816
   PubMed Web of Science ®Google Scholar
• GoASMozaffarianDRogerVLHeart disease and stroke statistics – 2014 update: a report from the American Heart AssociationCirculation20141293e28e29224352519
   PubMed Web of Science ®Google Scholar
• CoppensMEikelboomJWHartRGThe CHA2DS2-VASc score identifies those patients with atrial fibrillation and a CHADS2 score of 1 who are unlikely to benefit from oral anticoagulant therapyEur Heart J201334317017623018151
   PubMed Web of Science ®Google Scholar
• LipGYClementyNPericartLBanerjeeAFauchierLStroke and major bleeding risk in elderly patients aged ≥75 years with atrial fibrillation: the Loire Valley atrial fibrillation projectStroke201546114315025424474
   PubMed Web of Science ®Google Scholar
• ConnollySJEzekowitzMDYusufSDabigatran versus warfarin in patients with atrial fibrillationN Engl J Med2009361121139115119717844
   PubMed Web of Science ®Google Scholar
• PatelMRMahaffeyKWGargJRivaroxaban versus warfarin in nonvalvular atrial fibrillationN Engl J Med20113651088389121830957
   PubMed Web of Science ®Google Scholar
• GrangerCBAlexanderJHMcMurrayJJApixaban versus warfarin in patients with atrial fibrillationN Engl J Med20113651198199221870978
   PubMed Web of Science ®Google Scholar
• GiuglianoRPRuffCTBraunwaldEEdoxaban versus warfarin in patients with atrial fibrillationN Engl J Med2013369222093210424251359
   PubMed Web of Science ®Google Scholar
• EikelboomJWWallentinLConnollySJRisk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trialCirculation2011123212363237221576658
   PubMed Web of Science ®Google Scholar
• HalperinJLHankeyGJWojdylaDMEfficacy and safety of rivaroxaban compared with warfarin among elderly patients with nonvalvular atrial fibrillation in the Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF)Circulation2014130213814624895454
   PubMed Web of Science ®Google Scholar
• HalvorsenSAtarDYangHEfficacy and safety of apixaban compared with warfarin according to age for stroke prevention in atrial fibrillation: observations from the ARISTOTLE trialEur Heart J201435281864187224561548
   PubMed Web of Science ®Google Scholar
• LopesRDAl-KhatibSMWallentinLEfficacy and safety of apixaban compared with warfarin according to patient risk of stroke and of bleeding in atrial fibrillation: a secondary analysis of a randomised controlled trialLancet201238098551749175823036896
   PubMed Web of Science ®Google Scholar
• Toda KatoEGiuglianoRPRuffCTAbstract 16612: Efficacy and Safety of Edoxaban for the Management of Elderly Patients With Atrial Fibrillation: Engage AF-TIMI 48Circulation2014130A16612
   Web of Science ®Google Scholar
• RuffCTGiuglianoRPBraunwaldEComparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trialsLancet2014383992195596224315724
   PubMed Web of Science ®Google Scholar
• HartRGPearceLAAguilarMIMeta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillationAnn Intern Med20071461285786717577005
   PubMed Web of Science ®Google Scholar
• ConnollySJEikelboomJJoynerCApixaban in patients with atrial fibrillationN Engl J Med2011364980681721309657
   PubMed Web of Science ®Google Scholar
• SolimanEZPrineasRJGoASChronic kidney disease and prevalent atrial fibrillation: the Chronic Renal Insufficiency Cohort (CRIC)Am Heart J201015961102110720569726
   PubMed Web of Science ®Google Scholar
• BaberUHowardVJHalperinJLAssociation of chronic kidney disease with atrial fibrillation among adults in the United States: REasons for Geographic and Racial Differences in Stroke (REGARDS) StudyCirc Arrhythm Electrophysiol201141263221076159
   PubMed Web of Science ®Google Scholar
• HartRGPearceLAAsingerRWHerzogCAWarfarin in atrial fibrillation patients with moderate chronic kidney diseaseClin J Am Soc Nephrol20116112599260421903982
   PubMed Web of Science ®Google Scholar
• EikelboomJWConnollySJGaoPStroke risk and efficacy of apixaban in atrial fibrillation patients with moderate chronic kidney diseaseJ Stroke Cerebrovasc Dis201221642943522818021
   PubMed Web of Science ®Google Scholar
• PicciniJPStevensSRChangYRenal dysfunction as a predictor of stroke and systemic embolism in patients with nonvalvular atrial fibrillation: validation of the R(2)CHADS(2) index in the ROCKET AF (Rivaroxaban Once-daily, oral, direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (AnTicoagulation and Risk factors In Atrial fibrillation) study cohortsCirculation2013127222423223212720
   PubMed Web of Science ®Google Scholar
• BosMJKoudstaalPJHofmanABretelerMMDecreased glomerular filtration rate is a risk factor for hemorrhagic but not for ischemic stroke: the Rotterdam StudyStroke200738123127313217962600
   PubMed Web of Science ®Google Scholar
• OlesenJBLipGYHansenMLValidation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: nationwide cohort studyBMJ2011342d12421282258
   PubMed Web of Science ®Google Scholar
• BondeANLipGYKamperALNet clinical benefit of antithrombotic therapy in patients with atrial fibrillation and chronic kidney disease: a nationwide observational cohort studyJ Am Coll Cardiol201464232471248225500231
   PubMed Web of Science ®Google Scholar
• ChanKELazarusJMThadhaniRHakimRMWarfarin use associates with increased risk for stroke in hemodialysis patients with atrial fibrillationJ Am Soc Nephrol200920102223223319713308
   PubMed Web of Science ®Google Scholar
• ElliottMJZimmermanDHoldenRMWarfarin anticoagulation in hemodialysis patients: a systematic review of bleeding ratesAm J Kidney Dis200750343344017720522
   PubMed Web of Science ®Google Scholar
• ChanKELazarusJMThadhaniRHakimRMAnticoagulant and antiplatelet usage associates with mortality among hemodialysis patientsJ Am Soc Nephrol200920487288119297555
   PubMed Web of Science ®Google Scholar
• LimdiNABeasleyTMBairdMFKidney function influences warfarin responsiveness and hemorrhagic complicationsJ Am Soc Nephrol200920491292119225037
   PubMed Web of Science ®Google Scholar
• Eliquis® (apixaban) tablets for oral use [prescribing information]Princeton, NJBristol-Myers Squibb2012
   Google Scholar
• Savaysa® (edoxaban) tablets for oral use [prescribing information]Parsipanny, NJDaiichi Sankyo, Inc2015
   Google Scholar
• HarperPYoungLMerrimanEBleeding risk with dabigatran in the frail elderlyN Engl J Med2012366986486622375994
   PubMed Web of Science ®Google Scholar
• Pradaxa® (dabigatran etexilate mesylate) capsules for oral use [prescribing information]Ridgefield, CTBoehringer Ingelheim Pharmaceuticals, Inc2015
   Google Scholar
• StangierJRathgenKStahleHMazurDInfluence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallel-group, single-centre studyClin Pharmacokinet201049425926820214409
   PubMed Web of Science ®Google Scholar
• FoxKAPicciniJPWojdylaDPrevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairmentEur Heart J201132192387239421873708
   PubMed Web of Science ®Google Scholar
• Xarelto® (rivaroxaban) tablets for oral use [prescribing information]Leverkusen, GermanyBayer Pharma AG2014
   Google Scholar
• HohnloserSHHijaziZThomasLEfficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation: insights from the ARISTOTLE trialEur Heart J201233222821283022933567
   PubMed Web of Science ®Google Scholar
• US Food and Drug AdministrationFDA Draft Briefing Document for the Cardiovascular and Renal Drugs Advisory Committee (CRDAC)FDA2014 Available from: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/CardiovascularandRenalDrugsAdvisoryCommittee/UCM420704.pdfAccessed July 20, 2015
   Google Scholar
• AFFIRM InvestigatorsAtrial Fibrillation Follow-up Investigation of Rhythm Management. Baseline characteristics of patients with atrial fibrillation: the AFFIRM StudyAm Heart J20021436991100112075254
   PubMed Web of Science ®Google Scholar
• American College of Emergency PhysiciansSociety for Cardiovascular Angiography and InterventionsO’GaraPT2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice GuidelinesJ Am Coll Cardiol2013614e78e14023256914
   PubMed Web of Science ®Google Scholar
• AndersonJLAdamsCDAntmanEM2012 ACCF/AHA focused update incorporated into the ACCF/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice GuidelinesJ Am Coll Cardiol20136123e179e34723639841
   PubMed Web of Science ®Google Scholar
• MegaJLBraunwaldEMohanaveluSRivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trialLancet20093749683293819539361
   PubMed Web of Science ®Google Scholar
• MegaJLBraunwaldEWiviottSDRivaroxaban in patients with a recent acute coronary syndromeN Engl J Med2012366191922077192
   PubMed Web of Science ®Google Scholar
• MegaJLBraunwaldEMurphySARivaroxaban in patients stabilized after a ST-segment elevation myocardial infarction: results from the ATLAS ACS-2-TIMI-51 trial (Anti-Xa Therapy to Lower Cardiovascular Events in Addition to Standard Therapy in Subjects with Acute Coronary Syndrome-Thrombolysis In Myocardial Infarction-51)J Am Coll Cardiol201361181853185923500262
   PubMed Web of Science ®Google Scholar
• Task Force on the management of STseamiotESoCStegPGJamesSKESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevationEur Heart J201233202569261922922416
   PubMed Web of Science ®Google Scholar
• AlexanderJHLopesRDJamesSApixaban with antiplatelet therapy after acute coronary syndromeN Engl J Med2011365869970821780946
   PubMed Web of Science ®Google Scholar
• APPRAISE Steering Committee and InvestigatorsAlexanderJHBeckerRCApixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trialCirculation2009119222877288519470889
   PubMed Web of Science ®Google Scholar
• OldgrenJBudajAGrangerCBDabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trialEur Heart J201132222781278921551462
   PubMed Web of Science ®Google Scholar
• HohnloserSHOldgrenJYangSMyocardial ischemic events in patients with atrial fibrillation treated with dabigatran or warfarin in the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) trialCirculation2012125566967622215856
   PubMed Web of Science ®Google Scholar
• UchinoKHernandezAVDabigatran association with higher risk of acute coronary events: meta-analysis of noninferiority randomized controlled trialsArch Intern Med2012172539740222231617
   PubMed Web of Science ®Google Scholar
• ArtangRRomeENielsenJDVidailletHJMeta-analysis of randomized controlled trials on risk of myocardial infarction from the use of oral direct thrombin inhibitorsAm J Cardiol2013112121973197924075284
   PubMed Web of Science ®Google Scholar
• LarsenTBRasmussenLHSkjothFEfficacy and safety of dabigatran etexilate and warfarin in “real-world” patients with atrial fibrillation: a prospective nationwide cohort studyJ Am Coll Cardiol201361222264227323562920
   PubMed Web of Science ®Google Scholar
• GrahamDJReichmanMEWerneckeMCardiovascular, bleeding, and mortality risks in elderly Medicare patients treated with dabigatran or warfarin for nonvalvular atrial fibrillationCirculation2015131215716425359164
   PubMed Web of Science ®Google Scholar
• MakKHCoronary and mortality risk of novel oral antithrombotic agents: a meta-analysis of large randomised trialsBMJ Open201225
   Web of Science ®Google Scholar
• LokeYKPradhanSYeongJKKwokCSComparative coronary risks of apixaban, rivaroxaban and dabigatran: a meta-analysis and adjusted indirect comparisonBr J Clin Pharmacol201478470771724617578
   PubMed Web of Science ®Google Scholar
• SinghMMoningiSShahTAroraRSafety and efficacy of oral factor XA inhibitors in patients with acute coronary syndromes: a systemic meta-analysis of randomized controlled trialsJ Am Coll Cardiol201259E525E525
   Web of Science ®Google Scholar
• KomocsiAVorobcsukAKehlDAradiDUse of new-generation oral anticoagulant agents in patients receiving antiplatelet therapy after an acute coronary syndrome: systematic review and meta-analysis of randomized controlled trialsArch Intern Med2012172201537154523007264
   PubMedGoogle Scholar
• OldgrenJWallentinLAlexanderJHNew oral anticoagulants in addition to single or dual antiplatelet therapy after an acute coronary syndrome: a systematic review and meta-analysisEur Heart J201334221670168023470494
   PubMed Web of Science ®Google Scholar
• XuHRuffCTGiuglianoRPAbstract 19119: Concomitant Use of Antiplatelet Therapy with Edoxaban or Warfarin in Patients with Atrial Fibrillation in the ENGAGE AF-TIMI 48 TrialCirculation2014130A19119
   Web of Science ®Google Scholar
• HurlenMAbdelnoorMSmithPErikssenJArnesenHWarfarin, aspirin, or both after myocardial infarctionN Engl J Med20023471396997412324552
   PubMed Web of Science ®Google Scholar
• GuthrieBMcCowanCDaveyPSimpsonCRDreischulteTBarnettKHigh risk prescribing in primary care patients particularly vulnerable to adverse drug events: cross sectional population database analysis in Scottish general practiceBMJ2011342d351421693525
   PubMed Web of Science ®Google Scholar
• PicciniJPHellkampASMahaffeyKWAbstract 15686: Polypharmacy and the Efficacy and Safety of Rivaroxaban versus Warfarin in the Prevention of Stroke: Results From the ROCKET AF TrialCirculation2014130A15686
   Web of Science ®Google Scholar
• SkovJBladbjergEMSidelmannJVamosiMJespersenJPlenty of pills: polypharmacy prevails in patients of a Danish anticoagulant clinicEur J Clin Pharmacol201167111169117421562976
   PubMed Web of Science ®Google Scholar
• HartterSSennewaldRSchepersCBaumannSFritschHFriedmanJPharmacokinetic and pharmacodynamic effects of comedication of clopidogrel and dabigatran etexilate in healthy male volunteersEur J Clin Pharmacol201369332733922782539
   PubMed Web of Science ®Google Scholar
• LambertsMLipGYHansenMLRelation of nonsteroidal anti-inflammatory drugs to serious bleeding and thromboembolism risk in patients with atrial fibrillation receiving antithrombotic therapy: a nationwide cohort studyAnn Intern Med20141611069069825402512
   PubMed Web of Science ®Google Scholar
• GnothMJBuetehornUMuensterUSchwarzTSandmannSIn vitro and in vivo P-glycoprotein transport characteristics of rivaroxabanJ Pharmacol Exp Ther2011338137238021515813
   PubMed Web of Science ®Google Scholar
• WangLZhangDRaghavanNIn vitro assessment of metabolic drug-drug interaction potential of apixaban through cytochrome P450 phenotyping, inhibition, and induction studiesDrug Metab Dispos201038344845819940026
   PubMed Web of Science ®Google Scholar
• BathalaMSMasumotoHOgumaTHeLLowrieCMendellJPharmacokinetics, biotransformation, and mass balance of edoxaban, a selective, direct factor Xa inhibitor, in humansDrug Metab Dispos201240122250225522936313
   PubMed Web of Science ®Google Scholar
• KubitzaDBeckaMMueckWZuehlsdorfMSafety, tolerability, pharmacodynamics, and pharmacokinetics of rivaroxaban – an oral, direct factor Xa inhibitor – are not affected by aspirinJ Clin Pharmacol200646998199016920892
   PubMed Web of Science ®Google Scholar
• MueckWErikssonBIBauerKAPopulation pharmacokinetics and pharmacodynamics of rivaroxaban – an oral, direct factor Xa inhibitor – in patients undergoing major orthopaedic surgeryClin Pharmacokinet200847320321618307374
   PubMed Web of Science ®Google Scholar
• MueckWKubitzaDBeckaMCo-administration of rivaroxaban with drugs that share its elimination pathways: pharmacokinetic effects in healthy subjectsBr J Clin Pharmacol201376345546623305158
   PubMed Web of Science ®Google Scholar
• MendellJNoveckRJShiMPharmacokinetics of the direct factor Xa inhibitor edoxaban and digoxin administered alone and in combinationJ Cardiovasc Pharmacol201260433534123064240
   PubMed Web of Science ®Google Scholar
• OgataKMendell-HararyJTachibanaMClinical safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel factor Xa inhibitor edoxaban in healthy volunteersJ Clin Pharmacol201050774375320081065
   PubMed Web of Science ®Google Scholar
• ChinAPawMJDekkerJMFeskensEJSchoutenEGKromhoutDHow to select a frail elderly population? A comparison of three working definitionsJ Clin Epidemiol199952111015102110526994
   PubMed Web of Science ®Google Scholar
• FriedLPTangenCMWalstonJFrailty in older adults: evidence for a phenotypeJ Gerontol A Biol Sci Med Sci2001563M146M15611253156
   PubMed Web of Science ®Google Scholar
• PolidoroAStefanelliFCiacciarelliMPacelliADi SanzoDAlessandriCFrailty in patients affected by atrial fibrillationArch Gerontol Geriatr201357332532723706973
   PubMed Web of Science ®Google Scholar
• UdompanichSLipGYApostolakisSLaneDAAtrial fibrillation as a risk factor for cognitive impairment: a semi-systematic reviewQJM2013106979580223737509
   PubMed Web of Science ®Google Scholar
• FumagalliSTarantiniFGuarducciLAtrial fibrillation is a possible marker of frailty in hospitalized patients: results of the GIFA StudyAging Clin Exp Res201022212913319920409
   PubMed Web of Science ®Google Scholar
• Avila-FunesJACarcaillonLHelmerCIs frailty a prodromal stage of vascular dementia? Results from the Three-City StudyJ Am Geriatr Soc20126091708171222985143
   PubMed Web of Science ®Google Scholar
• FangMCChenJRichMWAtrial fibrillation in the elderlyAm J Med2007120648148717524745
   PubMed Web of Science ®Google Scholar
• O’BrienECSimonDNAllenLAReasons for warfarin discontinuation in the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF)Am Heart J2014168448749425262258
   PubMed Web of Science ®Google Scholar
• PereraVBajorekBVMatthewsSHilmerSNThe impact of frailty on the utilisation of antithrombotic therapy in older patients with atrial fibrillationAge Ageing200938215616219151165
   PubMed Web of Science ®Google Scholar
• FlakerGCPogueJYusufSCognitive function and anticoagulation control in patients with atrial fibrillationCirc Cardiovasc Qual Outcomes20103327728320233976
   PubMed Web of Science ®Google Scholar
• JacobsVWollerSCStevensSTime outside of therapeutic range in atrial fibrillation patients is associated with long-term risk of dementiaHeart Rhythm201411122206221325111326
   PubMed Web of Science ®Google Scholar
• DonzeJClairCHugBRisk of falls and major bleeds in patients on oral anticoagulation therapyAm J Med2012125877377822840664
   PubMed Web of Science ®Google Scholar
• Man-Son-HingMLaupacisAAnticoagulant-related bleeding in older persons with atrial fibrillation: physicians’ fears often unfoundedArch Intern Med2003163131580158612860581
   PubMed Web of Science ®Google Scholar
• Man-Son-HingMNicholGLauALaupacisAChoosing antithrombotic therapy for elderly patients with atrial fibrillation who are at risk for fallsArch Intern Med1999159767768510218746
   PubMedGoogle Scholar
• KatzSFordABMoskowitzRWJacksonBAJaffeMWStudies of Illness in the Aged. The Index of Adl: A Standardized Measure of Biological and Psychosocial FunctionJAMA196318591491914044222
   PubMed Web of Science ®Google Scholar
• ChatterjeeSSardarPBiondi-ZoccaiGKumbhaniDJNew oral anticoagulants and the risk of intracranial hemorrhage: traditional and Bayesian meta-analysis and mixed treatment comparison of randomized trials of new oral anticoagulants in atrial fibrillationJAMA Neurol201370121486149024166666
   PubMed Web of Science ®Google Scholar
• FriedLPFerrucciLDarerJWilliamsonJDAndersonGUntangling the concepts of disability, frailty, and comorbidity: implications for improved targeting and careJ Gerontol A Biol Sci Med Sci200459325526315031310
   PubMed Web of Science ®Google Scholar
• StangierJClinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilateClin Pharmacokinet200847528529518399711
   PubMed Web of Science ®Google Scholar
• KubitzaDBeckaMZuehlsdorfMMueckWBody weight has limited influence on the safety, tolerability, pharmacokinetics, or pharmacodynamics of rivaroxaban (BAY 59-7939) in healthy subjectsJ Clin Pharmacol200747221822617244773
   PubMed Web of Science ®Google Scholar
• PilottoAFerrucciLFranceschiMDevelopment and validation of a multidimensional prognostic index for one-year mortality from comprehensive geriatric assessment in hospitalized older patientsRejuvenation Res200811115115118173367
   PubMed Web of Science ®Google Scholar